Stocks - Q : Quality | V : Valuation | PT : Price Trend
Funds - P : Performance | Q : Quality
Funds - P : Performance | Q : Quality
BSE: 523844 | NSE: | Hospital & Healthcare Services | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Constronics Infra Ltd is a below average quality company.
The key valuation ratios of Constronics Infra Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Constronics Infra Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation Index Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -10.7% | -12.1% | -14.1% | -20.2% | -3% | 11.1% | -9.1% | 11.2% | 9.9% | 20.9% | - |
| Value Creation Index ⓘ | -1.8 | -1.9 | -2.0 | -2.4 | -1.2 | -0.2 | -1.7 | -0.2 | -0.3 | 0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 0.6 | 1.9 | 1.5 | 2.2 | 0.8 | 0.8 | 33 |
| Sales YoY Gr. | - | NA | NA | NA | NA | 241.8% | -18.6% | 41.8% | -62.2% | -6.1% | - |
| Adj EPS ⓘ | -0.1 | -0.1 | -0.1 | -0.2 | -0 | 0.1 | -0.1 | 0.2 | 0.1 | 1 | 2.2 |
| YoY Gr. | - | NA | NA | NA | NA | NA | -184.6% | NA | -66.7% | 1137.5% | - |
| BVPS (₹) ⓘ | 1.1 | 0.9 | 0.8 | 0 | 0 | 0.1 | 0 | 0.3 | 0.3 | 1.3 | 23.7 |
| Adj Net Profit ⓘ | -0.1 | -0.1 | -0.1 | -0.1 | 0 | 0.1 | -0.1 | 0.2 | 0.1 | 0.7 | 3 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | -0.1 | -0.1 | 0.1 | 0 | 0.1 | 0 | -0.2 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | -5.2 | -8 | 8.9 | 68.5 | 11 | 59.8 | -32.6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 7% | -20.5% | -6.1% | ||||
| Adj EPS ⓘ | NA | NA | NA | 1137.5% | ||||
| BVPSⓘ | 2.8% | NA | 306.2% | 294.1% | ||||
| Share Price | 33.4% | 72% | 106% | 30% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -10.8 | -12.2 | -14.4 | -42.4 | -171.9 | 192.4 | -138.8 | 167.3 | 25.7 | 118.1 | 17.5 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | -4.1 | 5 | -5.5 | 5.4 | 12.4 | 41.5 | 7 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | -4.1 | 5 | -5.1 | 8.1 | 6.9 | 92.8 | 8.3 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 27.4 | 436.1 | 8.5 | 46.1 | 5 | 3 | 5.7 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 614 | 187 | 185 | 130 | 244 | 376 | 356 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 4 | 8 | 3 | -1 | 28 | 146 | 337 |
Sales growth is good in last 4 quarters at 8087.86%
Return on Equity has declined versus last 3 years average to 17.50%
Sales growth has been subdued in last 3 years -20.46%
Net Profit has been subdued in last 3 years 0.00%
Debt to equity has increased versus last 3 years average to 5.73
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 2.2 | - |
| TTM Sales (₹ Cr.) | 33 | - |
| BVPS (₹.) ⓘ | 23.7 | - |
| Reserves (₹ Cr.) ⓘ | 17 | - |
| P/BV ⓘ | 2.79 | - |
| PE ⓘ | 30.07 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 50.64 / 157.70 |
| All Time Low / High (₹) | 0.50 / 157.70 |
| Market Cap (₹ Cr.) | 82.7 |
| Equity (₹ Cr.) | 12.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 42.2 |
| Mar'24 | YoY Gr. Rt. % | Jun'24 | YoY Gr. Rt. % | Sep'24 | YoY Gr. Rt. % | Dec'24 | YoY Gr. Rt. % | |
|---|---|---|---|---|---|---|---|---|
| Sales (₹ Cr.)ⓘ | 0.4 | 300 | 2.9 | 1942.9 | 13.8 | 19628.6 | 15.9 | 10480 |
| Adj EPS (₹) ⓘ | 0.9 | N/A | -0.1 | -225 | 1 | 9700 | 0.8 | 985.7 |
| Op. Profit Mgn % ⓘ | 52.25 | 5123 bps | -6.28 | -3369 bps | 8.64 | -1489 bps | 6.88 | -1542 bps |
| Net Profit Mgn % ⓘ | 159.00 | 16614 bps | -2.23 | -2223 bps | 8.86 | -143 bps | 6.01 | -2642 bps |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Company Name | CMP(₹) | |||||||
|---|---|---|---|---|---|---|---|---|
| Narayana Hrudayalay | 1,787.4 | -9.5 (-0.5%) | Small Cap | 5,018 | 38.4 | 15.7 | 46.6 | 10.8 |
| Aster DM Healthcare | 505.3 | -5.1 (-1%) | Small Cap | 3,699 | 105.6 | 5.5 | 4.8 | 7.2 |
| Dr. Lal Pathlabs | 2,906.6 | 118.9 (4.3%) | Small Cap | 1,967 | 59.5 | 19.5 | 48.9 | 11.4 |
| Indraprastha Medical | 402.9 | -17.2 (-4.1%) | Small Cap | 1,245 | 16.5 | 10 | 24.4 | 6.6 |
| RainbowChildrenS Med | 1,395.3 | -30.3 (-2.1%) | Small Cap | 1,237 | 23 | 17.4 | 60.7 | 9.9 |
| Krishna Inst.Medi | 674.1 | 7 (1%) | Small Cap | 1,222 | 6.4 | 19.3 | 104.7 | 13 |
| Kovai Medical Center | 5,595.6 | -2.9 (-0.1%) | Small Cap | 1,220 | 188.7 | 14.8 | 29.7 | 5.9 |
| Metropolis Health. | 1,751.6 | -11.3 (-0.6%) | Small Cap | 1,208 | 29.7 | 11 | 59 | 7.4 |
| HealthcareGlobal | 558.2 | -9.3 (-1.6%) | Small Cap | 1,099 | -0.8 | 3 | - | 6.6 |
| Jupiter Life Line | 1,500.7 | 1.9 (0.1%) | Small Cap | 911 | 28 | 16.7 | 53.7 | 7.1 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0.55 | 1.88 | 1.53 | 2.17 | 0.82 | 0.77 |
| Operating Expenses ⓘ | 0.08 | 0.09 | 0.09 | 0.30 | 0.57 | 1.79 | 1.61 | 2.06 | 0.72 | 0.45 |
| Manufacturing Costs | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0 |
| Material Costs | 0 | 0 | 0 | 0.19 | 0.43 | 1.62 | 1.28 | 1.63 | 0.30 | 0.05 |
| Employee Cost | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.12 | 0.15 | 0.13 | 0.12 |
| Other Costs ⓘ | 0.06 | 0.06 | 0.06 | 0.08 | 0.10 | 0.12 | 0.20 | 0.26 | 0.28 | 0.28 |
| Operating Profit ⓘ | -0.08 | -0.09 | -0.09 | -0.30 | -0.02 | 0.09 | -0.08 | 0.12 | 0.10 | 0.32 |
| Operating Profit Margin (%) | - | - | - | - | -4.1% | 5.0% | -5.5% | 5.4% | 12.4% | 41.4% |
| Other Income ⓘ | 0 | 0 | 0 | 0.17 | 0 | 0 | 0.01 | 0.01 | 0.03 | 0.49 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 |
| Depreciation ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0.03 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -0.09 | -0.09 | -0.09 | -0.13 | -0.02 | 0.09 | -0.08 | 0.10 | 0.09 | 0.77 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.08 | 0.04 | 0.06 |
| Profit After Tax | -0.09 | -0.09 | -0.09 | -0.13 | -0.02 | 0.09 | -0.08 | 0.17 | 0.06 | 0.72 |
| PAT Margin (%) | - | - | - | - | -4.1% | 4.9% | -5.1% | 8.0% | 6.9% | 92.8% |
| Adjusted EPS (₹) | -0.1 | -0.1 | -0.1 | -0.2 | 0.0 | 0.1 | -0.1 | 0.2 | 0.1 | 1.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 0.76 | 0.67 | 0.58 | 0.02 | 0 | 0.10 | 0.02 | 0.19 | 0.25 | 0.97 |
| Share Capital ⓘ | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 |
| Reserves ⓘ | -6.45 | -6.54 | -6.63 | -7.18 | -7.21 | -7.11 | -7.19 | -7.02 | -6.96 | -6.24 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 0 | 0 | 0 | 0.67 | 0.80 | 0.80 | 0.79 | 0.95 | 0.74 | 5.53 |
| Long Term Debt | 0 | 0 | 0 | 0.67 | 0 | 0 | 0.79 | 0.95 | 0.66 | 5.50 |
| Short Term Debt | 0 | 0 | 0 | 0 | 0.80 | 0.80 | 0 | 0 | 0.07 | 0.03 |
| Trade Payables | 0.01 | 0.04 | 0.04 | 0.01 | 0.32 | 0.01 | 0.01 | 0.03 | 0.01 | 0.03 |
| Others Liabilities ⓘ | 0.68 | 0.74 | 0.83 | 0.01 | 0.03 | 0.02 | 0.04 | -0.03 | 0 | 0.06 |
| Total Liabilities ⓘ | 1.45 | 1.45 | 1.45 | 0.71 | 1.16 | 0.94 | 0.86 | 1.15 | 0.99 | 6.58 |
Fixed Assets | ||||||||||
| Gross Block | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.21 | 0.22 | 0.22 |
| Accumulated Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.04 | 0.07 |
| Net Fixed Assetsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.20 | 0.18 | 0.15 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 0.19 | 0.19 | 0.19 | 0 | 0 | 0 | 0 | 0 | 0 | 0.45 |
| Trade Receivables | 0 | 0 | 0 | 0 | 0.41 | 0.05 | 0 | 0.04 | 0.15 | 0.06 |
Cash Equivalents  ⓘ
| 0 | 0 | 0 | 0 | 0.04 | 0.12 | 0.12 | 0.15 | 0.52 | 5.14 |
| Others Assetsⓘ | 1.26 | 1.26 | 1.26 | 0.71 | 0.72 | 0.75 | 0.74 | 0.76 | 0.14 | 0.79 |
| Total Assets ⓘ | 1.45 | 1.45 | 1.45 | 0.71 | 1.16 | 0.94 | 0.86 | 1.15 | 0.99 | 6.58 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0 | 0 | 0 | -0.13 | -0.10 | 0.09 | 0.01 | 0.09 | 0.01 | -0.17 |
| PBT ⓘ | -0.09 | -0.09 | -0.09 | -0.13 | -0.02 | 0.09 | -0.08 | 0.10 | 0.09 | 0.77 |
| Adjustment ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.03 | -0.45 |
| Changes in Working Capital ⓘ | 0.08 | 0.09 | 0.09 | 0 | -0.08 | -0 | 0.09 | -0.03 | -0.1 | -0.43 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.02 | -0.06 |
| Cash Flow From Investing Activity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.21 | 0.65 | -0.53 |
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.21 | -0.01 | 0 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.53 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.66 | 0 |
| Cash Flow From Financing Activityⓘ | 0 | 0 | 0 | 0.13 | 0.14 | 0 | -0.02 | 0.15 | -0.30 | 5.31 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.30 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.01 | -0.01 | -0.01 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0.13 | 0.14 | 0 | -0.02 | 0.16 | -0.29 | -0.98 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 0 | 0.04 | 0.09 | -0.01 | 0.03 | 0.37 | 4.62 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -10.77 | -12.17 | -14.42 | -42.43 | N/A | 192.41 | -138.79 | 167.27 | 25.7 | 118.08 |
| ROCE (%) | -10.74 | -12.13 | -14.1 | -20.15 | N/A | 11.11 | -9.14 | 11.22 | 9.93 | 20.9 |
| Asset Turnover Ratio | 0 | 0 | 0 | 0 | 0.58 | 1.8 | 1.7 | 2.16 | 0.77 | 0.2 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | 1 | N/A | 0.53 | 0.17 | -0.24 |
| Working Capital Days | ||||||||||
| Receivable Days | 0 | 0 | 0 | 0 | 272 | 44 | 0 | 7 | 43 | 50 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 214 |
| Payable Days | 0 | 0 | 0 | 46 | 143 | 38 | 4 | 5 | 25 | 152 |
Invicta Meditek Limited (Invicta) incorporated in 1992 is a Public Limited company engaged in the manufacture of quality Orthopaedic Implants and Instruments.
Invicta Meditek manufacture the quality Orthopaedic Implants and Instruments. Invicta serves the field of Orthopaedics by supplying products for Total Joint Replacement systems, Trauma Implants and Associated Instruments. The product range also includes implants for Hemi-Arthroplasty, all types of Dynamic Compression and round hole plates, Screws with Cortical, Cancellous profiles, special thread sizes and in all diameters (with and without cannulation) and DHS/ DCS systems. The Joint Replacement Systems for Knee, Hip, Shoulder and Ankle are manufactured under license from Endotec Inc., USA.
Invicta has established a full-fledged machine shop with sophisticated, state of the art machinery required to meet the challenging, stringent quality requirements of the Orthopaedic implants and the high levels of accuracy required for the instruments used in joint replacement and other critical surgical operations.
Invicta lays special emphasis on achieving customer satisfaction by demonstrating the ability to consistently provide products that meet and exceed customer requirements. The Quality Control Department is equipped with the latest tools and instruments maintaining the strict quality standards demanded by the orthopaedic community.
Invicta’s product portfolio includes:-Total Joint Replacements for Knee, Hip, Ankle, Shoulder (under license from Endotec Inc., USA) -trauma implants (plates, screws, nails etc) -associated instrumentation
Product range of the company includes:
Achievements/ recognition :
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Download APP
